Catalent
0.0 %
12.59 %
Yet to be announced
Company Overview
Catalent, Inc. is a global provider of development sciences and manufacturing platforms for medicines, biologics, cell and gene therapies, and consumer health products. The company partners with pharmaceutical, biotechnology, and consumer health companies to develop and deliver better treatments to patients worldwide.
The company operates through multiple segments including Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
Revenue Sources
PassBased on review of Catalent's financial statements and business operations, the company's revenue is primarily derived from pharmaceutical development and manufacturing services. None of their core business activities involve prohibited products or services like alcohol, tobacco, gambling, or interest-based financial services.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $1.02b | $1.15b | - | $60.0m | 0.00% | 5.22% |
| June 30, 2024 | $1.3b | $1.26b | - | $65.0m | 0.00% | 5.18% |
| March 31, 2024 | $1.07b | $1.16b | - | $65.0m | 0.00% | 5.62% |
| Dec. 31, 2023 | $1.02b | $1.21b | - | $66.0m | 0.00% | 5.47% |
Analyzing the last four quarters: Interest expense to total expense ratios ranged from 4.8% to 5.5% of total expenses. This exceeds the 5% threshold for at least two consecutive quarters, indicating interest plays a material role in the company's operations.
Operational Ethics
PassA review of Catalent's global operations and partnerships shows no evidence of significant ongoing associations with entities involved in human rights violations. While the company operates globally, including in China, there is no clear evidence of material ties to the Chinese Communist Party or the state of Israel.
Comments